$MED

Chard Daniel R sold $226K of MED (indirect holdings)

Chard Daniel R sold 19,089 indirectly-held shares of MEDIFAST INC (MED) at an average of $11.85 ($11.73–$11.98, $0.23M total) across 2 trades over 2026-09-28 to 2026-09-29 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chard Daniel R
Published Oct 1, 2026, 12:04 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 1, 2026, 12:32 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$MED
Bearish
medium confidence
Mentioned
$MED
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$MEDBearishLow
01

Why it matters

The disclosed sale is a primary source but modest in size, likely resulting in limited price movement.

02

Market read

A small insider sell by a director may cause slight bearish sentiment but is unlikely to move the stock materially.

03

What to watch

Potential upcoming corporate actions or earnings that may have prompted the director to lock in cash.

Relevance 3/10Novelty 3/10Timing: post-filing

Background

Form 4 filings disclose insider transactions; this filing reports a director's sale under a 10b5‑1 plan.

Company-level read

Ticker impact

$MEDBearishMedium confidence
Context

Director Chard Daniel R sold 19,091 shares for $226,288, reducing his holdings to 130,609 shares.

Expected impact

likely modest downside as investors price in the director's sell-off

Evidence & confidence

A $226K sale by a director is a primary disclosure but the amount is small; market reaction is typically limited but can nudge the stock lower.

Market effects

Minimal impact on the health and nutrition sector; the sale is company‑specific.

No broader regional effect.

Limited to MED investors.

Counterpoint

The sale could be routine portfolio rebalancing unrelated to company fundamentals.

Key entities

  • Medifast Inc.

    US‑listed health and nutrition company (ticker MED).

  • Chard Daniel R

    Director of Medifast who executed the sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$MEDMed

5 insightful analyst questions from Medifast’s Q3 earnings call

Medifast's Q3 revenue exceeded expectations but declined year-over-year. Management cited the Trilogy brand's success and improved coach productivity. Analysts questioned coach engagement, competition with GLP-1 medications, and cost reduction. The stock is trading at $12.50. Key focus areas include Trilogy adoption, coach productivity, and cost efficiencies.

$MEDHigh

Why Medifast (MED) stock is trading up today

Medifast (MED) shares rose 6.2% after Q3 results beat expectations, with adjusted EBITDA of $1.9M. CEO Nick Johnson highlighted new product launches and guidance for Q4 revenue of $55M-$75M. Full-year revenue is expected at $280M-$300M, with a GAAP loss of $1.80-$2.05 per share.

$MEDMed

Medifast Inc (MED) (Q3 2026) Earnings Call Highlights: Revenue Stabilizes Near $75 Million

Medifast Inc (MED) reported Q3 2026 revenue of $72M, down 19.4% YoY, with revenue stabilizing near $75M for four quarters. CEO Nicholas Johnson highlighted high engagement and productivity among coaches, despite a decline in active coach numbers. The company expects continued productivity growth and cost efficiencies. Q4 revenue guidance is $55M-$75M, with EPS of $0-$0.25. Medifast has $172.5M in cash and no debt, with a target of profitability in Q4 2026.

$MEDMed

Medifast, Inc. Q3 2026 Earnings Call Summary

Medifast (MED) reported a 19.4% revenue decline in Q3 2026, attributing it to lower active coach counts due to GLP-1 medication adoption. The company is transitioning to a metabolic health system called Trilogy and implementing cost-cutting measures. Q4 2026 revenue is expected between $55M and $75M, with a focus on profitability and long-term growth. Management sees GLP-1s as a catalyst for consumer interest rather than a direct threat.

$MEDMed

What Medifast (MED) Said on Its Q3 Earnings Call

Medifast (MED) reported a Q3 operating loss of $19.4M, including restructuring charges. The company introduced new products and highlighted GLP-1 medications' impact on client conversations. Medifast forecasts Q4 revenue of $55M-$75M and full-year 2026 revenue of $280M-$300M, aiming for profitability in Q4.